Name

CNX Therapeutics

Legal name

CNX Therapeutics Limited

Website

https://cnx-therapeutics.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Specialty pharmaceuticals
• CNS therapeutics
• Critical care medicines
• Pharmaceutical distribution
• Drug licensing

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Product Licensing and Distribution: CNX licenses and distributes pharmaceutical products for CNS, critical care, and other conditions across 60+ markets globally through direct operations and strategic partnerships.
2. Acquisition and Integration: Growth strategy based on acquiring established pharmaceutical brands from larger companies and integrating them into CNX's European commercial platform.
3. Licensing Deals: Exclusive rights to market and sell licensed products across European markets, with upfront payments and potential milestone payments. Example: EUR 750,000 upfront for Sumatriptan Alginate Film from Klaria.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

CNX Therapeutics licenses, distributes, and commercializes a portfolio of specialty medicines focused on Central Nervous System (CNS), critical care, and oncology support conditions. The company operates a buy-and-build platform model that acquires and in-licenses established pharmaceutical brands from larger pharmaceutical companies that choose to divest non-core assets, supplying 25+ products across 60+ markets. It also develops proprietary value-added medicines (VAM), including a novel Sumatriptan Alginate Film for migraine.

Product overview

CNX Therapeutics is a specialty pharmaceutical company that commercializes and distributes a portfolio of medicines for central nervous system (CNS), critical care, and other therapeutic conditions. The company operates a platform-based model with over 20 marketed products (including 14 injectables and 6 CNS products) distributed across 60+ markets globally. The portfolio consists of acquired branded products (Sativex®, Ethyol®, Tacrolimus infusion), licensed products (Sumatriptan Alginate Film), and value-added medicines (controlled-release formulations), supplemented by strategic acquisitions of companies (Synchrony Pharma) and product portfolios from major pharma companies (Eisai, Sanofi, Clinigen). Products are distributed both directly and through strategic partnerships, with a focus on hospital-initiated treatments in CNS, critical care, and oncology.

Differentiator

Problem solved

Functional benefit

Brands

• Ethyol: FDA-approved cytoprotective agent indicated to reduce cumulative renal toxicity associated with cisplatin chemotherapy and reduce xerostomia in head and neck cancer patients.
• Sativex (nabiximols)
• Tacrolimus Infusion

Products and services

• Sativex (nabiximols) Sativex (nabiximols) is an oromucosal cannabis-based spray indicated as add-on treatment for multiple sclerosis (MS) spasticity in adult patients. It is sold to healthcare providers, hospitals, and specialty pharmacies treating MS patients.
• Ethyol (amifostine) Ethyol (amifostine) is a cytoprotective agent used to reduce cumulative renal toxicity associated with repeated cisplatin administration in advanced ovarian cancer, and to reduce the incidence of moderate-to-severe xerostomia in patients receiving postoperative radiation for head and neck cancer. It is sold to oncology hospitals and treatment centers.
• Tacrolimus 5 mg/ml Concentrate for Solution for Infusion Tacrolimus 5 mg/ml concentrate is an immunosuppressant infusion used for prophylaxis of transplant rejection in adult and pediatric patients receiving allogeneic liver, kidney, or heart transplants. It is supplied to transplant hospitals and specialist healthcare providers.
• Sumatriptan Alginate Film (migraine therapy) Sumatriptan Alginate Film is a value-added medicine (VAM) formulation of sumatriptan delivered via a proprietary alginate-based oral trans-mucosal film technology for acute migraine treatment. It is targeted at healthcare providers, neurologists, and patients seeking faster-acting migraine relief than conventional oral sumatriptan tablets.
• Loxapac and Parkinane LP (Eisai CNS Portfolio) Loxapac (loxapine) is an antipsychotic used in schizophrenia and acute agitation, and Parkinane LP (trihexyphenidyl) is an anticholinergic used in Parkinson's disease. Both are sold to mental health hospitals, neurologists, and specialty psychiatry clinics.
• Clinigen Cancer Support Therapies portfolio Clinigen Cancer Support Therapies is a portfolio of oncology supportive care medicines used to manage side effects and complications of cancer treatment, sold to oncology hospitals and treatment centers.
• Sanofi CNS Portfolio brands The Sanofi CNS Portfolio comprises multiple established CNS medicines for conditions including anxiety, depression, and epilepsy, sold to hospitals, psychiatrists, neurologists, and specialty pharmacies across multiple markets.
• Controlled-release value-added medicine for pain A controlled-release value-added medicine (VAM) formulation for pain management being developed by CNX to improve dosing convenience and patient outcomes versus existing pain therapies. Targeted at healthcare providers and pain specialists.

Quantifiable outcome

• First UK pharma company to achieve B Corp certification with score of 103.2
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Seven partnerships are on record, tiered core, former and supporting.

• Legacy Pharma Inc. SEZCcoreChannel Partner/ Reseller/ Distributor · 26 June 2026US commercial partnership for launch of Ethyol (amifostine) in July 2026. Legacy Pharma, a specialty pharmaceutical distribution platform, commercializes amifostine across the United States through specialty pharmacy and traditional wholesale channels. This is CNX's first commercial partnership in the United States.
• PharmanoviacoreOEM/ Whitelabel/ Licensing Partner · 2 April 2026Acquired rights to Tacrolimus 5 mg/ml concentrate for solution for infusion, the first generic version of Prograf (Astellas Pharma). Transaction signed April 1, 2026.
• AlmirallcoreChannel Partner/ Reseller/ Distributor · 3 November 2025Existing commercial partner for Sativex (nabiximols) in European markets. Almirall holds commercial rights for the product in key European territories.
• Jazz PharmaceuticalsformerOthers · 3 November 2025Sativex acquired from Jazz Pharmaceuticals in October 2025. Jazz provided transition support under a Transition Service Agreement during the handover.
• IHP (International Health Partners)supportingStrategic or Co-development Partner · 1 April 2025Partnership to expand global medicine access, working together to ensure essential medicines reach patients in underserved markets.
• Klaria Pharma Holding ABcoreStrategic or Co-development Partner · 13 January 2025Strategic licensing deal for Sumatriptan Alginate Film across Europe (EU markets, UK, Norway, Switzerland) with initial focus on Germany, Spain, Italy. Klaria received EUR 750,000 upfront payment. CNX has exclusive rights to market and sell the product.
• Social Mobility FoundationsupportingStrategic or Co-development Partner · 1 January 2024Partnership bringing five interns from underrepresented backgrounds into 12-month roles across HR, Legal, Quality, Data, and Commercial teams. Expanded to include work placement and mentoring programme in 2026.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pharmanovia: UK- and Europe-focused specialty pharma platform with a comparable buy-and-build strategy of acquiring mature, off-patent and divested brands from larger pharma companies. Directly comparable business model to CNX, including recent Tacrolimus acquisition (counterparty to CNX).
• Almirall: Spanish specialty pharmaceutical company focused on medical dermatology and specialty care across Europe; existing commercial partner of CNX for Sativex. Operates a similar European specialty pharma model with focused therapeutic categories and partnered distribution.
• Galen: UK and Ireland-headquartered specialty pharmaceutical company marketing established prescription medicines across CNS, pain and women's health. Closely comparable business model of acquiring and commercializing mature specialty brands in European markets.
• Norgine: European specialty pharmaceutical company headquartered in the Netherlands with a focus on hospital and specialty products including gastroenterology and CNS. Comparable European-focused, specialty branded pharma model with strong hospital channel presence.
• Consilient Health: Ireland-headquartered specialty pharmaceutical company marketing branded prescription medicines in CNS, women's health and urology across European markets. Directly comparable in size, therapeutic focus and European specialty pharma model.

Broad incumbents

• Stada Arzneimittel: German-headquartered European specialty and generics pharmaceutical company with a broad portfolio of branded specialty products and generics across CNS, critical care and hospital injectables — overlapping with CNX's therapeutic focus and geographic footprint but at significantly larger scale.
• Recordati: Italian specialty pharmaceutical group with a strong European presence in CNS, rare diseases and hospital products. Comparable focus on specialty branded medicines across multiple European geographies, though materially larger and more diversified than CNX.
• Hikma Pharmaceuticals: UK-listed specialty generics and branded pharmaceutical company with significant European and Middle East presence. Comparable in product categories (CNS, hospital injectables) and in acquiring/integrating mature assets, though substantially larger and more diversified geographically.
• Sobi (Swedish Orphan Biovitrum): Swedish specialty pharmaceutical company focused on rare diseases and specialty care across Europe and globally. Comparable in being a Europe-headquartered specialty pharma platform with acquired and licensed products across therapeutic niches.

Regional players

• Kyowa Kirin: Japan-based specialty pharmaceutical company with growing European operations focused on CNS and rare disease specialty products. Comparable in CNS therapeutic focus and value-added specialty product positioning, though anchored in a different primary geography.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cnx-therapeutics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CNX Therapeutics